May 17, 2021
Union Defence Minister Rajnath Singh hands over anti-Covid drug 2-DG to Health Minister Harsh Vardhan - PTI
Union Defence Minister Rajnath Singh hands over anti-Covid drug 2-DG to Health Minister Harsh Vardhan - PTI×
First batch of 2-DG dedicated to nation
The first batch of the anti-Covid drug 2-DG (2-deoxy-D-glucose), developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS) scientists jointly with their counterparts at Dr Reddy’s Laboratories in Hyderabad, was dedicated to the nation by Defence Minister Rajnath Singh on Monday.
The INMAS, a lab under the Defence Research and Development Organisation, had developed the molecule for treating cancer, but it has not been repurposed for treating Covid-19 infection as adjuvant as well as standalone medication.
Updated:
Developed with DRL, it reduces oxygen-dependence in patients
Share Article
AAA
Defence Minister Rajnath Singh hands over the first batch of 2-DG anti Covid drug to the Union Health Minister Harsh Vardhan, in New Delhi on May 17, 2021. Photo: Twitter/@rajnathsingh
Developed with DRL, it reduces oxygen-dependence in patients
The first batch of the adjunct COVID therapy drug, 2-deoxy-D-glucose (2-DG) developed by the Defence Research and Development Organisation (DRDO) along with Dr Reddy’s Laboratories (DRL), Hyderabad was on Monday released for emergency use. Defence Minister Rajnath Singh formally handed over the drug to Health Minister Dr Harsh Vardhan.
“One box each of the sachets of the drug were handed over to Dr. Randeep Guleria, Director All India Institute of Medical Sciences (AIIMS) and Lt. Gen. Sunil Kant of Armed Forces Medical Services (AFMS). More will be handed over to different hospitals across the country for emergency use,” a Defence M
COVID-19: The 2-G drug had shown promising results in its phase 2 and phase 3 clinical trials.
New Delhi:
An anti-coronavirus drug developed by Defence Research and Development Organisation (DRDO) will be launched tomorrow, with Union Defence Minister Rajnath Singh distributing around 10,000 doses to some hospitals in the national capital.
The drug, called 2-deoxy-D-glucose or 2-DG, was developed by a DRDO lab in collaboration with the Hyderabad-based pharma giant, Dr Reddy s Laboratories. The Drugs Controller General of India (DCGI), the country s top drug regulator, has approved the medicine for emergency use.
The drug had shown promising results in its phase 2 and phase 3 clinical trials. The medicine was found to be safe for COVID-19 patients in phase 2 trials, conducted between May and October last year. It was found to be effective in cutting short the hospital stays of Covid patients and reducing their supplemental oxygen dependence.
2-DG s therapeutic use for COVID-19 is set to begin in the coming week. However, there are several gaps in the information surrounding the drug trials and a lack of available data.
Pharma major Dr Reddy’s Laboratories Ltd net profit decreased 28 per cent at ₹554 crore in the fourth quarter ended March 31, 2021 as against ₹764 crore in the corresponding quarter of the previous